ValiRx plc (GB:VAL) has released an update.
ValiRx PLC, a life science company specializing in early-stage cancer therapeutics and women’s health, reported a decrease in total comprehensive loss to £2,037,701 for the year ended December 31, 2023, along with a reduction in research and development costs. Despite a challenging economic environment, the company has initiated new partnerships, expanded its laboratory services through Inaphaea BioLabs, and pursued a build-and-buy strategy, acquiring Imagen Therapeutics’ assets. These strategic moves are set against the backdrop of the company’s reliance on future fundraising to maintain operations.
For further insights into GB:VAL stock, check out TipRanks’ Stock Analysis page.
